Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma

Cancer

Volumn 79, Issue 6, 1997, Pages 1094-1099

  Tournigand, Christophe ^a   Louvet, Christophe ^a   De Gramont, Aimery ^a   Lucchi, Elisabeth ^a   Seitz, Jean François ^b   Mal, Frédéric ^c   Raymond, Eric ^a   Cady, Jean ^d   Carola, Elisabeth ^e   Krulik, Marcel ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c INSTITUT MUTUALISTE MONTSOURIS   (France)

^d Clinique Geoffroy Saint Hilaire   (France)

^e Hopital de Senlis   (France)

Author keywords

5 fluorouracil infusion; colorectal carcinoma; Interferon; leucovorin

Indexed keywords

ALPHA2A INTERFERON; FLUOROURACIL; FOLINIC ACID; PARACETAMOL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; DIARRHEA; DRUG MEGADOSE; FEMALE; FLU LIKE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; LUNG METASTASIS; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERON ALFA-2A; LEUCOVORIN; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 0030995214     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970315)79:6<1094::AID-CNCR6>3.0.CO;2-G     Document Type: Article

References (30)

1. Sotos GA, Grogan L, Allegra CJ. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treatment Rev 1994;20:11-49.
2. Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967-72.
3. Advanced colorectal cancer meta-analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
4. Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, et al. Fluorouracil and recombinant alfa-2a interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;12:1769-75.
5. Wadler S. Antineoplastic activity of the combination of 5-fluorouracil and interferon: preclinical and clinical results. Semin Oncol 1992;19(4 Suppl):38-40.
6. Grem JL, McAtee N, Murphy RF, Balis FM, Steinberg SM, Hamilton JM, et al. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol 1991; 9:1811-20.
7. Milano G, Fischel JL, Etienne MC, Renee N, Formento P, Thyss A, et al. Inhibition of dihydropyrimidine dehydrogenase by alpha-interferon: experimental data on human tumor cell lines. Cancer Chemother Pharmacol 1994;34(2): 147-52.
8. Schwartz EL, Hoffman M, O'Connor CJ. Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Res Commun 1992; 182:1232-9.
9. Kase S, Kubota T, Watanabe M, Teramoto T, Kitajima M, Hoffman RM. Recombinant human interferon alpha-2a increases 5-fluorouracil efficacy by elevating fluoridine concentration in tumor tissue. Anticancer Res 1994;14:1155-9.
10. Löffler TM, Weber FW, Hausamen TU. Double modulation of weekly high-dose continuous infusion 5-fluorouracil with leucovorin and interferon-alpha 2b in metastatic colorectal cancer. Presented at the International Symposium on Novel Approaches to Selective Treatment of Human Solid Tumors: Laboratory and Clinical Correlation, September 9-12, 1992, Roswell Park, Buffalo, NY.
11. de Gramont A, Krulik M, Cady J, Lagadec B, Maisani JE, Loiseau JP, et al. High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988;24:1499-1503.
12. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. A prospectively randomized trial comparing 5-FU bolus with low dose leucovorin and 5-FU bolus plus continuous infusion with high-dose leucovorin for advanced colorectal cancer. In: Perry MC, editor. Program/ Proceedings of the American Society of Clinical Oncology, 1995 May 20-23; Los Angeles CA. Alexandria: American Society of Clinical Oncology, 1995: 194.
13. de Gramont A, Thirion P. Rationale for high-dose folinic acid and 5-fluorouracil in short continuous infusion in colorectal cancer. Continuous Infusion Newsletter 1994;2:8-15.
14. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, World Health Organization, 1979.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
16. York M, Greco LV, Figlin RA, Einhorn L, Man T, Cockey L, et al. A randomized phase III trial comparing 5-FU with or without interferon alpha 2a for advanced colorectal cancer. In: Perry MC, editor. Program/Proceedings of the American Society of Clinical Oncology; 1993 May 16-18; Orlando, FL. Alexandria: American Society of Clinical Oncology, 1993:200.
17. Cellerino R, Antognoli S, Giustini L, Acito L, Marcellini M, Bavosi M, et al. A randomized study of fluorouracil with or without alpha-interferon in advanced colorectal cancer. In: Perry MC, editor. Program/Proceedings of the American Society of Clinical Oncology; 1994 May 14-17; Dallas, TX. Alexandria: American Society of Clinical Oncology, 1994:217.
18. Kreuser ED, Streit M, Küchler T, Mathias M, Berdel WE, Thiel E. A multicenter randomized trial with the assessment of the quality of life in patients with metastatic colorectal carcinoma given either folinic acid or interferon a-2b as modulator of 5-fluorouracil. In: Perry MC, editor. Program/ Proceedings of the American Society of Clinical Oncology; 1995 May 20-23; Los Angeles, CA. Alexandria: American Society of Clinical Oncology, 1995:202.
19. Dreyfus B, Dufour P, Husseini F, Cure H, Olivier JP, Dumas F, et al. Randomized study of 5-fluorouracil versus 5-FU + alpha 2A interferon as treatment for metastatic colorectal carcinoma [abstract 0262]. In: Program and Abstracts of the Fifth International Congress on Anticancer Chemotherapy, January 31-February 3, 1995, Paris, France. 1995:113.
20. Recchia F, Nuzzo A, Lombardo M, Lalli A, Fabiani F, Fanini R, et al. 5-fluorouracil and high-dose folinic acid chemotherapy with or without alfa 2b interferon in advanced colorectal cancer: preliminary report of a randomized trial. In: Perry MC, editor. Program/Proceedings of the American Society of Clinical Oncology; 1992 May 17-19; San Diego, CA. Alexandria: American Society of Clinical Oncology, 1992:162.
21. Cortesi E, D'Aprile M, Di Palma M, Farris A, Massida B, Cristofanilli M, et al. Advanced colorectal cancer: a phase II study of chemoimmunotherapy with IFN alpha 2b + 5-FU continuous infusion or 5-FU + folinic acid. In: Perry MC, editor. Program/Proceedings of the American Society of Clinical Oncology; 1992 May 17-19; San Diego, CA. Alexandria: American Society of Clinical Oncology, 1992:183.
22. Corfu-A study group. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 1995;13:921-8.
23. Kosmidis P, Tsavaris N, Skarlos D, Pavlidis N, Beer M, Theocharis D, et al. Fluorouracil and folinic acid with or without a2b-interferon in advanced colorectal cancer: a prospective randomized trial. In: Perry MC, editor. Program/ Proceedings of the American Society of Clinical Oncology; 1993 May 16-18; Orlando, FL. Alexandria: American Society of Clinical Oncology, 1993:211.
24. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989;7:425-32.
25. Rougier Ph, Paillot B, Laplanche A, Morvan F, Benhamed M, Seitz JF, et al. End results of a multicentric randomized trial comparing 5-FU in continuous infusion to bolus administration in measurable metastatic colorectal cancer. In: Perry MC, editor. Program/Proceedings of the American Society of Clinical Oncology; 1992 May 17-19; San Diego, CA. Alexandria: American Society of Clinical Oncology, 1992:163.
26. Findlay MP, Cunningham D, Hill ME, Ellis P, Young H, Hickish T, et al. Protracted venous infusion 5-FU ± interferon-alpha 2b in patients with advanced colorectal cancer: results of a phase III trial and a parallel study measuring tumor fluorodeoxyglucose with positron emission tomography. In: Perry MC, editor. Program/Proceedings of the American Society of Clinical Oncology; 1994 May 14-17; Dallas, TX. Alexandria: American Society of Clinical Oncology, 1994:193.
27. Seymour MT, Slevin M, Cunningham D, Kerr D, James R, Lederman J, et al. A randomized assessment of interferon-α2a as a modulator of 5-fluorouracil and leucovorin in advanced colorectal cancer. In: Perry MC, editor. Program/ Proceedings of the American Society of Clinical Oncology; 1994 May 14-17; Dallas, TX. Alexandria: American Society of Clinical Oncology, 1994:209.
28. Köhne CH, Schmoll HJ, Wilke HJ, Käufer C, Rauschecker H, Andreesen R, et al. Weekly high-dose infusional 5-fluorouracil plus leucovorin vs FU plus α-interferon vs FU plus LV plus IFN in advanced colorectal cancer: results of a multicenter randomized trial. In: Perry MC, editor. Program/ Proceedings of the American Society of Clinical Oncology; 1995 May 20-23; Los Angeles, CA. Alexandria: American Society of Clinical Oncology, 1995:194.
29. de Gramont, Tournigand C, Louvet C, Varette C, Raymond E, Vignoud J, et al. Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48h infusion in pretreated metastatic colorectal cancer [abstract]. Can J Infect Dis 1995;6(Suppl C):458C.
30. Beerblock K, Rinaldi Y, André T, Grangé JD, Louvet C, Tournigand C, et al. Bi-weekly high-dose folinic acid and 5-fluorouracil 48 infusion in metastatic colorectal cancer. In: Perry MC, editor. Program/Proceedings of the American Society of Clinical Oncology; 1996 May 18-21; Philadelphia, PA. Alexandria: American Society of Clinical Oncology, 1996:212.